HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kell alloimmunization, hemolytic disease of the newborn, and perinatal management.

Abstract
The relative frequency of Kell (K:1) antibodies in pregnant women and a series of cases of Kell hemolytic disease of newborns were evaluated to review the strategy of managing potential disease. Among reproductive-aged women, Kell antibodies are about 60% as frequent as Rho (D) antibodies, but Kell disease is only 3% as common as Rho hemolytic disease. The reason is related to frequent transfusion-alloimmunization by Kell antigen and the low frequency of the K:1 gene among fathers. Kell hemolysis is severe in about half of cases. Amniocentesis is indicated in only a few circumstances: previous child with erythroblastosis fetalis, significant increase in maternal Coombs titer, presence of Kell antigen in the father, and after comparison of the relative risks of hemolytic disease and amniocentesis in each patient. Screening for Kell antigen before transfusing premenopausal women would be a means of avoiding erythroblastosis, but the rarity of severe disease does not justify this approach.
AuthorsR E Wenk, P Goldstein, J K Felix
JournalObstetrics and gynecology (Obstet Gynecol) Vol. 66 Issue 4 Pg. 473-6 (Oct 1985) ISSN: 0029-7844 [Print] United States
PMID3931011 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antibodies
  • Blood Group Antigens
  • Kell Blood-Group System
Topics
  • Adolescent
  • Adult
  • Antibodies (analysis)
  • Blood Group Antigens (immunology)
  • Blood Group Incompatibility (etiology, immunology)
  • Erythroblastosis, Fetal (epidemiology, immunology)
  • Female
  • Humans
  • Infant, Newborn
  • Kell Blood-Group System (immunology)
  • Male
  • Middle Aged
  • Perinatology
  • Phenotype
  • Pregnancy
  • Retrospective Studies
  • Rh Isoimmunization (epidemiology)
  • Serologic Tests
  • Transfusion Reaction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: